Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Pasireotide (Signifor) peptide icon, one bubble per amino acidPasireotide (Signifor)6 residuesPXWKYFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Pasireotide (Signifor)

Beginner tier: 600 mcg, 2x daily · FDA label

MetabolicFDA Approved
12 h half-life·Injection

Also known as: SOM230, Signifor, Signifor LAR

Seventy-three percent of patients develop hyperglycemia. That number defines pasireotide (brand name Signifor) more than any other statistic. This cyclohexapeptide somatostatin analog binds all five SSTR subtypes, with 30- to 40-fold higher affinity for SSTR5 than octreotide. The FDA approved it in December 2012 for Cushing's disease and in 2014 as a long-acting release formulation for acromegaly. In the Phase III trial [1], urinary free cortisol normalized in 15% of patients on 600 mcg twice daily and 26% on 900 mcg. Median urinary free cortisol fell by about half by month 2. Endocrinologists prescribe it when pituitary surgery fails or isn't possible, and blood glucose monitoring starts before the first dose.

What Is Pasireotide (Signifor)?

Thirty- to 40-fold higher SSTR5 affinity than octreotide. That receptor selectivity is the entire clinical premise behind pasireotide.

Pasireotide (Signifor, SOM230, CAS 396091-73-9) is a cyclohexapeptide somatostatin analog that binds all five somatostatin receptor subtypes (SSTR1 through SSTR5). Corticotroph adenomas in Cushing's disease predominantly express SSTR5, not SSTR2. First-generation analogs like octreotide and lanreotide barely touch SSTR5; pasireotide saturates it. That difference gave Cushing's disease patients the first medical therapy proven to target the pituitary tumor directly.

The Phase III trial [1] enrolled adults with persistent or recurrent Cushing's disease and tracked urinary free cortisol. At six months, UFC normalized in 15% of patients on 600 mcg twice daily and 26% on 900 mcg. Over 50% had meaningful reductions even without full normalization. A 2025 real-world monocentric cohort of 19 patients [2] pushed that number to 52.6% normalization, suggesting careful patient selection matters.

For acromegaly, the story is different. Signifor LAR (40 to 60 mg intramuscular every 28 days) targets patients who failed octreotide or lanreotide. In PAOLA [3], 15% on 40 mg and 20% on 60 mg reached biochemical control at 24 weeks. Patients kept on octreotide or lanreotide reached 0%. A 2024 systematic review and meta-analysis (409 patients across 12 studies)[4] reported 57.9% IGF-1 control in real-world practice. Part of that gap is the endpoint: PAOLA also required GH below 2.5 mcg/L. The rest likely reflects better responder identification over time.

The limitation is metabolic. Hyperglycemia hits approximately 73% of patients because SSTR5 activation suppresses insulin and incretin secretion from pancreatic beta cells. Three of 19 patients in the 2025 cohort discontinued specifically because of glucose complications. This is a drug that works, but the metabolic cost of treatment requires aggressive co-management from day one.

How Pasireotide (Signifor) Works

Somatostatin receptors come in five subtypes. First-generation analogs like octreotide hit SSTR2 hard and mostly ignore the rest. Pasireotide flips the script.

Bruns and colleagues mapped the binding profile in 2002, with high affinity for SSTR1, SSTR2, SSTR3 and SSTR5 [8]. At SSTR1 and SSTR5, its affinity runs 30 to 40 times higher than octreotide's. For Cushing's disease, SSTR5 is the receptor that matters because corticotroph adenomas express it far more than SSTR2.

When pasireotide binds SSTR5 on corticotroph tumor cells, it activates Gi/Go-coupled inhibitory signaling. Intracellular cAMP drops. POMC gene transcription slows. ACTH secretion decreases. Less ACTH reaches the adrenals; cortisol output falls. Separately, phosphotyrosine phosphatases SHP-1 and SHP-2 activate, feeding into MAPK/ERK pathway inhibition. That arm carries antiproliferative effects on the tumor itself.

In acromegaly, the mechanism shifts to dual SSTR2 and SSTR5 engagement on somatotroph adenomas. Tumors that lost SSTR2 expression (and stopped responding to octreotide) may still respond through the SSTR5 pathway.

The hyperglycemia problem traces back to the same receptor. SSTR5 sits on pancreatic beta cells and enteroendocrine cells. Activation suppresses insulin secretion directly and blocks incretin hormones GLP-1 and GIP. Meanwhile, SSTR2-mediated glucagon suppression is relatively weaker with pasireotide than with octreotide. The net effect is diabetogenic.

Pasireotide (Signifor) Benefits

  • Pasireotide benefits center on pituitary tumor control and cortisol normalization in two rare endocrine conditions.
  • First FDA-approved medical therapy that directly targets the pituitary corticotroph tumor in Cushing's disease, upstream of cortisol production at the adrenal level.
  • Normalizes urinary free cortisol at six months in 15% (600 mcg) to 26% (900 mcg) of patients in the important Phase III trial [1]; a 2025 real-world cohort of 19 patients found 52.6% normalization with careful patient selection [2].
  • Biochemical control (GH below 2.5 mcg/L, normal IGF-1) in 15 to 20% of PAOLA patients uncontrolled on octreotide or lanreotide [3]. Patients kept on those drugs reached 0%. Real-world data across 409 patients puts IGF-1 control alone at 57.9% [4].
  • Patients who respond report resolution of Cushingoid features: weight loss, reduced facial swelling, improved blood pressure, and better quality of life within three to six months.
  • The LAR formulation for acromegaly requires just one intramuscular injection every 28 days, a 12-hour half-life for the subcutaneous version, and pre-filled ampules that need no reconstitution.
  • Tumor volume reduction documented in both corticotroph and somatotroph adenomas; sustained IGF-1 normalization confirmed at 36 months in acromegaly responders [5].

Pasireotide (Signifor): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 13 key studies·FDA-approved

FDA-approved for Cushing's disease (SC, 600-900 mcg BID) and acromegaly (LAR, 40-60 mg monthly IM).

Dosing studied: Cushing's disease: 600–900 mcg SC twice daily. Acromegaly: 40–60 mg IM every 28 days (LAR formulation only).
Read the evidence (key study, limitations)

Pivotal Phase III trial normalized UFC in 15% (600 mcg) and 26% (900 mcg) of Cushing's patients at month 6; median UFC fell by about half by month 2. 2025 real-world monocentric cohort (n=19) showed 52.6% normalization. Acromegaly systematic review/meta-analysis (2024, n=409, 12 studies) found 57.9% IGF-1 control in first-generation SSA-resistant patients, well above PAOLA's 15 to 20%. PAOLA also required GH below 2.5 mcg/L, and real-world responder selection may explain part of the gap. Hyperglycemia (73%) is the dominant treatment-limiting adverse effect.

Key Study

Phase III Cushing's trial (PMID 22397653) + acromegaly real-world meta-analysis 2024 (PMID 39527181, n=409) + PAOLA trial (PMID 25260838)

Limitations

Only ~26–53% of Cushing's patients achieve UFC normalization: no validated biomarker identifies responders before treatment. Hyperglycemia in ~73% frequently requires antidiabetic therapy initiation. Cholelithiasis in up to 30% with prolonged use. QT prolongation and bradycardia require cardiac monitoring. Cost ~$62–66K/year retail with no generic or legal compounded alternative. No head-to-head data vs. cabergoline for Cushing's disease.

Community Experience
Weak
2.5/5
Based on clinical cohorts 19–409 patients

No off-label, self-directed, or bodybuilding community use exists: pasireotide is a prescription specialty drug used exclusively under endocrinology supervision.

Community dosing: Follows FDA label exactly: no community dose modifications documented.
Read the reports (what users report 6, common issues 7)

Patient community sentiment (r/Cushings, pituitary patient forums) centers on real-world tolerability: hyperglycemia burden is the dominant concern. Responders report meaningful symptom improvement; non-responders face difficult conversations about alternative therapies (cabergoline, osilodrostat, bilateral adrenalectomy).

What users report (6)
  • Meaningful UFC reduction in majority of Cushing's patients even without full normalization
  • Weight loss and resolution of Cushingoid features (moon face, buffalo hump) in responders
  • Headache resolution and improved quality of life documented in case series
  • Tumor volume reduction in some corticotroph adenomas
  • Once-monthly LAR dosing for acromegaly reduces injection burden vs. daily SC formulations
  • Biochemical control in ~58% of first-gen SSA-resistant acromegaly patients (real-world data)
Common issues (7)
  • Hyperglycemia requiring new diabetes diagnosis and medication in previously non-diabetic patients
  • Diarrhea and GI distress most prominent in first 2–4 weeks of therapy
  • Extreme cost ($62–66K/year) with complex insurance prior authorization requirements
  • Gallstone formation with prolonged use (up to 30%)
  • Fatigue, headache, and decreased appetite during treatment
  • Non-responder rate: ~47–74% of Cushing's patients do not normalize UFC
  • 3 of 19 patients discontinued due to hyperglycemia complications in 2025 cohort (PMID 40075004)
Science-Only Evidence

Pasireotide has no off-label or community self-administration use. All efficacy and safety data comes from clinical trials and real-world medical cohorts. Community sentiment reflects patients receiving prescribed endocrinology therapy, not self-directed peptide use. There is no 'community protocol' to compare against the science.

Pasireotide (Signifor) Dosage Guide

FDA LabelSignifor (pasireotide) FDA Prescribing Information (2020)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner600 mcg2x Daily
Moderate600 mcg2x Daily
Aggressive900 mcg2x Daily
Note:

Pasireotide is not a research peptide you'll reconstitute from a lyophilized vial. Signifor SC comes as pre-filled, single-use ampules in three concentrations: 0.3 mg/mL, 0.6 mg/mL, and 0.9 mg/mL. Each ampule holds 1 mL. You draw the full contents and inject subcutaneously into the abdomen or thigh.

The 600 mcg dose uses one 0.6 mg/mL ampule per injection, twice daily. The 900 mcg dose uses one 0.9 mg/mL ampule. No measuring, no bacteriostatic water, no math. Verify the ampule concentration matches your prescribed dose before each shot.

Spacing matters. Doses need to be roughly 12 hours apart. Intervals stretching beyond 14 hours reduce steady-state plasma exposure and may compromise efficacy.

The most common beginner mistake: ignoring blood glucose. Buy a glucometer before you start. Test fasting glucose daily for the first two weeks. If readings cross 126 mg/dL, contact your endocrinologist about starting metformin. This is not something to wait on.

Store ampules at 2 to 8 degrees C. Do not freeze. Protect from light. Each ampule is single-use; discard any leftover.

Cycling

Pasireotide is used as continuous long-term therapy and is not cycled. For Cushing's disease, treatment is maintained as long as clinical benefit is observed. Blood glucose must be monitored weekly for the first 2-3 months and at least quarterly thereafter.

Calculate your Pasireotide (Signifor) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Pasireotide (Signifor) Protocols by Goal

intermediateFDA LabelContinuous long-term therapy: not cycled. Treatment maintained as long as clinical benefit is observed. Response assessed at 2 months (dose titration) and 6 months (efficacy determination).
Initiation: Signifor SC
Wk 1–8
600 mcg · Twice daily (~12 hours apart) · Subcutaneous (abdomen or thigh)
Dose titration (if UFC >2x ULN at 2-month assessment)
Wk 9+
900 mcg · Twice daily · Subcutaneous

Expected: UFC normalization in ~26–53% of patients. UFC reduction (without full normalization) in >50%. Improvement in clinical signs of hypercortisolism (weight loss, blood pressure normalization, skin changes) within 3–6 months in responders.

Monitor: Blood glucose: before starting + weekly for first 2–3 months + at least quarterly. UFC: baseline, 2 months, 6 months, then every 6 months. ECG: baseline and day 21. LFTs: baseline, 6 weeks, 12 weeks, then periodically. Gallbladder ultrasound: baseline and every 6–12 months. HbA1c: quarterly. Serum cortisol: monitor for adrenal insufficiency as UFC normalizes.

How to Inject Pasireotide (Signifor)

  1. 1
    Step 1

    Confirm your prescribed dose and select the correct pre-filled ampule: 0.3 mg/mL (300 mcg), 0.6 mg/mL (600 mcg), or 0.9 mg/mL (900 mcg). Each ampule contains 1 mL of ready-to-inject solution.

  2. 2
    Step 2

    Remove the ampule from refrigeration and allow it to reach room temperature for a few minutes. Clean the injection site (abdomen or outer thigh) with an alcohol swab.

  3. 3
    Snap open the ampule at the colored dot

    Draw the full 1 mL into an insulin syringe or the provided syringe. On a standard 100-unit insulin syringe, 1 mL equals 100 units. You inject the full 100 units for every dose regardless of concentration.

  4. 4
    Pinch a fold of skin at the injection site

    Insert the needle at a 45- to 90-degree angle. A 29- to 31-gauge, 0.5-inch needle works well for subcutaneous delivery.

  5. 5
    Inject the full ampule contents slowly and steadily

    Withdraw the needle, apply gentle pressure with a cotton pad. Discard the ampule and syringe in a sharps container.

  6. 6
    Step 6

    Administer the second daily dose approximately 12 hours later. Rotate injection sites each time: left abdomen, right abdomen, left thigh, right thigh.

  7. 7
    Record your injection time and site

    Test fasting blood glucose the next morning, especially during the first two weeks of therapy.

For Signifor LAR (acromegaly): This is a clinic-only procedure. A healthcare provider reconstitutes the lyophilized microsphere kit immediately before injection and delivers 40 to 60 mg as a deep intramuscular gluteal injection every 28 days. Patients cannot self-administer the LAR formulation.

Pasireotide (Signifor) Stacking Protocols

Works With

Cabergoline (dopamine agonist)

Sequential or combination therapy in refractory Cushing's disease. Cabergoline targets D2 dopamine receptors on corticotroph tumors: mechanism independent of SSTR5. Some centers add cabergoline if pasireotide achieves only partial UFC reduction. Not a standard first-line combination but used in treatment-refractory cases.

Metformin

First-line antidiabetic for pasireotide-induced hyperglycemia in a 2024 algorithm (PMID 39735646), starting in prediabetes. For acromegaly patients with diabetes above its thresholds (fasting glucose over 126 mg/dL, glucose after meals over 200 mg/dL, or HbA1c over 7%), the algorithm adds an SGLT-2 inhibitor or a GLP-1 receptor agonist, and metformin can be added. The authors note metformin does not interact with pasireotide.

Metformin 500 mg BID, titrate to 1000 mg BID based on glucose response and GI tolerability. Check eGFR before starting.

GLP-1 receptor agonist (e.g., semaglutide, liraglutide)

Second-line antidiabetic when metformin is insufficient or poorly tolerated for pasireotide-induced hyperglycemia. GLP-1 RAs address the insulin secretion defect via a non-SSTR pathway. Per a 2024 algorithm (PMID 39735646). In about 25% of Cushing's and 50% of acromegaly patients, the high blood sugar needs no drug or responds to diet and oral agents.

Avoid

QT-prolonging drugs (class IA/III antiarrhythmics, fluoroquinolone antibiotics, antipsychotics, azithromycin)

Additive QT prolongation. Pasireotide independently prolongs QTc; combination dramatically increases risk of torsades de pointes. ECG monitoring mandatory when combination cannot be avoided.

Do not combine
Narrow therapeutic index CYP3A4 substrates (cyclosporine, tacrolimus)

Pasireotide is a weak CYP3A4 inhibitor and may reduce intestinal absorption of cyclosporine. Cyclosporine blood levels may fall, risking transplant rejection. Monitor drug levels closely if co-administration required.

Beta-blockers and non-dihydropyridine calcium channel blockers (verapamil, diltiazem)

Additive bradycardia. Pasireotide slows heart rate via somatostatin receptor effects on the sinoatrial node; combination may cause clinically significant bradycardia or heart block.

Insulin (without active dose adjustment and monitoring)

Pasireotide profoundly suppresses insulin and incretin secretion. Patients on insulin before pasireotide initiation require close monitoring as glucose dynamics change significantly. Insulin requirements may increase, then fluctuate as antidiabetic regimen is adjusted.

Estimated Cost

Brand Price
Signifor SC: ~$21,537 per 60-ampule carton (1-month supply at 600 mcg BID); ~$62,427/year at standard dose. Signifor LAR: ~$21,262 per injection; ~$65,859/year at monthly dosing. Manufacturer (Recordati Rare Diseases) co-pay card available ($20/month for commercially insured). Patient assistance programs may be available for qualifying uninsured patients. Canadian pharmacy pricing substantially lower but requires valid Rx.

Pricing updated 2026-04-09

Pasireotide (Signifor) Side Effects

Hyperglycemia. Not the mild, transient kind. Pasireotide causes clinically significant glucose elevation in approximately 73% of patients, often requiring initiation of antidiabetic therapy in people who were not diabetic before starting treatment. The mechanism is direct: SSTR5 suppresses insulin secretion from pancreatic beta cells and inhibits incretin hormones GLP-1 and GIP. Three of 19 patients in a 2025 real-world cohort [2] had to stop pasireotide entirely because of glucose complications. Blood glucose monitoring is not a suggestion. It starts before the first injection and continues weekly for the first two to three months.

A 2024 review proposed a treatment algorithm (Witek 2024)[6]. Metformin comes first, starting at the prediabetes stage. A GLP-1 receptor agonist comes next, or an SGLT-2 inhibitor with kidney disease or heart failure. Insulin is the last step. The authors left DPP-4 inhibitors out because they appear ineffective for pasireotide-induced hyperglycemia. In about 25% of Cushing's and 50% of acromegaly patients, the high blood sugar needs no drug or responds to diet and oral agents. Recordati Rare Diseases funded the review.

Gastrointestinal side effects are common and front-loaded. Diarrhea affects roughly 58% of patients. Nausea hits 52%. Abdominal pain occurs in about 24%. These GI effects are worst in the first two to four weeks and usually become tolerable for most people by month two. Small frequent meals and loperamide for diarrhea help during that adjustment period.

Cholelithiasis develops in up to 30% of patients on prolonged somatostatin analog therapy. A 2026 analysis pooled polycystic kidney and liver disease trials with FDA adverse event reports [7]. Its authors concluded that "younger patients or those receiving pasireotide are at higher risk of cholelithiasis." Somatostatin receptors reduce gallbladder contractility; bile stasis follows. Baseline gallbladder ultrasound is required, with repeat imaging every 6 to 12 months. Right upper quadrant pain warrants immediate evaluation. Asymptomatic stones can be monitored; symptomatic cholecystitis may require surgical consultation.

QT prolongation is documented and requires ECG monitoring at baseline and day 21. The risk increases with concomitant QT-prolonging medications. If QTc exceeds 500 ms, the drug should be stopped.

Hepatic enzyme elevations (ALT and AST) occur in 5 to 10% of patients. Liver function tests at baseline, six weeks, and 12 weeks are standard protocol. Enzymes exceeding five times the upper limit of normal require discontinuation.

Injection site reactions affect about 17% of patients using the subcutaneous formulation. Rotating between abdomen and thigh helps. Bradycardia is a known class effect of somatostatin analogs. Combination with beta-blockers or non-dihydropyridine calcium channel blockers carries additive risk.

One counterintuitive risk: adrenal insufficiency. As cortisol levels drop in Cushing's disease responders, the long-suppressed HPA axis may not recover fast enough. Profound fatigue, orthostatic hypotension, and nausea are the warning signs. Hydrocortisone supplementation (10 to 20 mg per day) may be needed until adrenal function recovers.

Pregnancy is a contraindication. Animal studies showed embryotoxicity (Category C). Whether pasireotide passes into breast milk is unknown.

Common Issues & Solutions

Hyperglycemia in first 1–7 days: Expected: do not stop pasireotide without contacting prescriber. Start metformin 500 mg BID. If fasting glucose >300 mg/dL or symptomatic (polyuria, polydipsia, altered mental status), urgent endocrinology contact required.

No UFC reduction at 2-month assessment: Confirm 12-hour dosing adherence (intervals >14 hours significantly reduce steady-state exposure). Titrate to 900 mcg BID if tolerated. If no response at maximum dose by 6 months, discuss alternative medical therapy (cabergoline, osilodrostat, bilateral adrenalectomy) with endocrinologist.

Severe GI effects (diarrhea, nausea) in first 2–4 weeks: Usually self-limiting. Loperamide 2 mg after each loose stool for diarrhea; small frequent meals and antiemetics (ondansetron) for nausea. If intolerable, temporary dose reduction to 300 mcg BID with re-escalation after 2 weeks.

Adrenal insufficiency signs (profound fatigue, orthostatic hypotension, nausea) during UFC normalization: Paradoxical risk: long-suppressed HPA axis cannot respond normally as cortisol drops. Requires hydrocortisone supplementation (typically 10–20 mg/day) until adrenal recovery. Do not stop pasireotide abruptly.

Right upper quadrant pain or biliary colic during treatment: Gallstone formation in up to 30% with prolonged somatostatin analog use. Confirm with right upper quadrant ultrasound. Cholecystitis requires surgical consultation and pasireotide reassessment. Asymptomatic gallstones: continue with increased monitoring frequency.

Ask AI about this page

Ask AI for a second opinion on Pasireotide (Signifor) dosing and side effects

Contraindications

  • Hypersensitivity to pasireotide or any component of the formulation
  • Uncontrolled diabetes mellitus (high risk of severe hyperglycemia)
  • Severe hepatic impairment (Child-Pugh C): pasireotide clearance is significantly reduced
  • Pregnancy (Category C: embryotoxicity in animal studies)
  • Breastfeeding (unknown whether excreted in breast milk)
  • Congenital long QT syndrome or uncontrolled risk factors for QT prolongation
  • Pre-existing symptomatic cholelithiasis (risk of worsening gallbladder disease)
  • Clinically significant bradycardia or conduction abnormalities

Drug Interactions

  • Insulin and oral hypoglycemics: Dose adjustments very frequently needed; pasireotide profoundly suppresses insulin secretion
  • QT-prolonging drugs (antiarrhythmics, fluoroquinolones, antipsychotics): Additive QT prolongation risk; ECG monitoring mandatory
  • Beta-blockers and calcium channel blockers: Additive bradycardia and heart rate effects
  • Cyclosporine: Pasireotide may decrease cyclosporine blood levels by reducing intestinal absorption
  • CYP3A4 substrates: Pasireotide is a weak CYP3A4 inhibitor; use caution with narrow therapeutic index drugs
  • Bromocriptine: Increased bioavailability of bromocriptine; monitor for dopamine agonist side effects
  • Ketoconazole: May be used concomitantly but overlapping hepatotoxicity and QT effects require close monitoring
  • Additive bradycardia. Pasireotide slows heart rate via somatostatin receptor effects on the sinoatrial node; combination may cause clinically significant bradycardia or heart block.

Product Quality

Recommended Monitoring

TestWhenTarget
Blood glucose (fasting)Before starting, daily for first 2 weeks, weekly for first 2–3 months, then at least quarterlyFasting glucose <126 mg/dL; 2-hour postprandial <180 mg/dL
HbA1cBaseline, then every 3 months for first year, then every 6 months<7.0% for most patients; <8.0% in elderly or complex patients
24-hour urinary free cortisol (UFC)Baseline, 2 months, 6 months, then every 6 months (Cushing's disease)Within local laboratory upper limit of normal
IGF-1 and random GHBaseline and every 3 months (acromegaly)IGF-1 within age-adjusted normal range; random GH <2.5 mcg/L
ECG (QTc interval)Baseline and day 21, then as clinically indicated (especially if QT-prolonging drugs added)QTc <450 ms (men) / <460 ms (women); stop drug if QTc >500 ms
Liver function tests (ALT, AST, bilirubin)Baseline, 6 weeks, 12 weeks, then periodically<3x ULN; hold drug if >5x ULN
Gallbladder ultrasoundBaseline and every 6–12 monthsNo new stones, sludge, or biliary dilation
Serum cortisol (morning)Periodically in Cushing's patients achieving UFC normalizationMorning cortisol >5 mcg/dL to exclude adrenal insufficiency
Blood glucose (fasting)

Hyperglycemia in ~73% of patients: early detection prevents DKA and guides antidiabetic therapy initiation

HbA1c

Long-term glycemic control: guides antidiabetic medication management

24-hour urinary free cortisol (UFC)

Primary efficacy endpoint: determines response and need for dose titration; also screens for developing adrenal insufficiency

IGF-1 and random GH

Primary biochemical efficacy endpoints for acromegaly

ECG (QTc interval)

QT prolongation documented in clinical trials; risk increases with electrolyte abnormalities or concomitant QT-prolonging medications

Liver function tests (ALT, AST, bilirubin)

Hepatic enzyme elevations in 5–10% of patients; severe hepatic impairment requires dose adjustment or discontinuation

Gallbladder ultrasound

Cholelithiasis in up to 30% with prolonged SSA use; EudraVigilance data (PMID 39770473) shows higher hepatobiliary stone rate vs. comparator SSAs

Serum cortisol (morning)

Risk of relative adrenal insufficiency as long-suppressed HPA axis recovers; requires glucocorticoid supplementation if symptomatic

Pasireotide (Signifor) Before and After

First dose
0-12 hours

Peak plasma levels within 1-2 hours. ACTH and cortisol suppression begins within hours. GI side effects may occur early. Blood glucose may rise within hours.

Days 1-14

Urinary free cortisol begins decreasing. Hyperglycemia typically manifests: daily blood glucose monitoring. GI side effects most prevalent but usually diminish.

Weeks 2-8

Dose titration based on UFC response. Blood glucose management established with appropriate antidiabetic therapy.

Months 2-6

UFC normalization assessed. Approximately 26% achieve normalization by 6 months; over 50% show meaningful reductions. Clinical signs of Cushing's begin improving.

Months 6-12+

Continued long-term therapy with periodic monitoring of UFC, glucose, HbA1c, liver enzymes, ECG, and gallbladder status. Tumor volume reduction may be observable on MRI.

What to Expect

Day 1 through 14, Initiation: Plasma levels peak within one to two hours of the first subcutaneous dose. ACTH and cortisol suppression begins within hours. Hyperglycemia typically shows up by day one to three, so daily glucose monitoring is not optional. Patients report nausea, diarrhea, and injection site soreness during this window. Most find the GI effects manageable within one to two weeks.

Weeks 2 through 8, Dose titration window: UFC starts measurably declining in patients who will respond. The antidiabetic regimen gets established and stabilized. An ECG check happens at day 21. Responders begin noticing early cortisol symptom reduction: better sleep quality, the beginning of weight normalization. GI side effects subside for most patients by week four. Glucose management remains the active challenge.

Months 2 through 6, Response assessment: This is the decision point. UFC normalization happens in roughly 26 to 53% of patients by six months. Over 50% show meaningful reductions even without full normalization. Clinical Cushing's features start improving: weight loss, blood pressure drops, skin changes reverse. Responders report a real quality-of-life shift. Non-responders discuss switching to cabergoline, osilodrostat, or bilateral adrenalectomy with their endocrinologist.

Months 6 through 24 and beyond, Long-term maintenance: Responders stay on continuous therapy. Tumor volume reduction may show on MRI at 12 months or later. For acromegaly patients on the LAR formulation, sustained IGF-1 normalization has been documented at 36 months [5]. The ongoing reality is metabolic management: glucose monitoring, gallstone surveillance, and fatigue are the three persistent challenges. Some patients develop permanent glucose abnormalities that persist even after eventual discontinuation.

Detailed Timeline: Science vs Community

Day 1–14
Science

Peak plasma levels within 1–2 hours of first SC dose. ACTH and cortisol suppression begins within hours. Hyperglycemia typically manifests day 1–3. GI side effects most prominent in this window.

Community

Patients report GI discomfort (nausea, diarrhea) and glucose spikes requiring monitoring. Injection site soreness common. Most find GI effects manageable within 1–2 weeks.

Weeks 2–8
Science

UFC begins measurably declining in responders. Antidiabetic regimen established and stabilized. Dose titration decision at 2-month UFC. ECG check at day 21.

Community

Responders begin noticing early cortisol symptom reduction: improved sleep quality, beginning of weight normalization. GI side effects subside for most patients by week 4.

Months 2–6
Science

UFC normalization in ~26–53% by 6 months. Meaningful UFC reduction in >50%. Clinical Cushing's features begin improving: weight loss, blood pressure, skin changes.

Community

Responders report significant quality-of-life improvement: weight loss, resolution of facial swelling and muscle weakness, better energy. Non-responders transition to alternative therapy. Glucose management is the primary ongoing challenge for both groups.

Months 6–24+
Science

Sustained UFC control in responders. Possible tumor volume reduction on MRI at 12+ months. Sustained IGF-1 normalization documented at 36 months in acromegaly responders (PMID 38362280). Ongoing monitoring for all identified toxicities.

Community

Long-term patients report stable disease control but persistent metabolic burden: established diabetes management, gallstone surveillance, and fatigue as the main ongoing challenges. Some develop permanent glucose abnormalities.

Pharmacokinetics

Half-Life
12h
Bioavailability
SC: >90%
Tmax
SC: 1-2 hours
Data Confidence
high

Source: FDA prescribing information

Pharmacokinetics: Active Dose Over Time

t½ = ~12 hours (subcutaneous)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
6
Structure
Cyclic
Sequence
PXWKYF
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 396091-73-9 (free base); 820232-50-6 (diaspartate salt)PubChem 9941444 (opens in a new tab)

Who Should Consider Pasireotide (Signifor)

  • Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative
  • Patients with acromegaly who have had inadequate response to first-generation somatostatin analogs
  • Individuals with persistent or recurrent Cushing's disease after transsphenoidal surgery
  • Acromegaly patients with tumors expressing predominantly SSTR5 rather than SSTR2
  • Patients requiring bridging therapy before or after pituitary radiation therapy

Related Peptides

What Changed for Pasireotide (Signifor)

  1. Safety

    Corrected Oct 18, 2026: pasireotide's glucose plan follows Witek 2024, metformin then a GLP-1 agonist or SGLT-2 inhibitor, no DPP-4, per PubMed (PMID 39735646).

    Before: Metformin 500 mg twice daily above 126 mg/dL, then DPP-4 inhibitors or GLP-1 receptor agonists After: Metformin first from prediabetes, then a GLP-1 receptor agonist or an SGLT-2 inhibitor, insulin last; DPP-4 inhibitors left out of the algorithm

    What this does not mean: High blood sugar is still the main risk, in about 73% of patients. The review sets no metformin dose and starts metformin at prediabetes, not at 126 mg/dL.

    Source: Front Endocrinol 2024, Pasireotide-induced hyperglycemia in Cushing's disease and acromegaly: a clinical perspective and algorithms proposal (Witek et al.), full text PMC11672337 (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  2. Safety

    Younger age and pasireotide were tied to higher gallstone risk across three somatostatin analogs, per Clin Transl Gastroenterol, Jul 20, 2026.

    Before: Gallstones described per drug as a somatostatin analog effect, with no comparison across octreotide, lanreotide and pasireotide. After: Adds a 2026 analysis: gallstones were the most common biliary event for all three; its authors found higher risk in younger patients and with pasireotide.

    What this does not mean: Adverse event reports cannot give rates, and the trials were in polycystic kidney and liver disease. It does not mean octreotide or lanreotide carry a low gallstone risk.

    Also covers: Octreotide (Sandostatin), Lanreotide (Somatuline Depot)

    Source: Clinical and Translational Gastroenterology 2026, octreotide, lanreotide and pasireotide in polycystic kidney and liver disease (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 8, 202613 Citations

References

  1. [1]A 12-month Phase 3 study of pasireotide in Cushing's disease (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Efficacy and safety of pasireotide in patients with Cushing's disease: a monocentric cohort study (Endocrine 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial (Gadelha et al., Lancet Diabetes Endocrinol 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Real-world evidence of effectiveness and safety of pasireotide in acromegaly: a systematic review and meta-analysis (Biagetti et al., Rev Endocr Metab Disord 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study (Favero et al., Front Endocrinol 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal (Front Endocrinol (Lausanne) 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]Comparative efficacy and safety of octreotide, lanreotide, and pasireotide in ADPKD and polycystic liver disease: network meta-analysis with FAERS data (Mei et al., Clin Transl Gastroenterol 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile (Bruns et al., Eur J Endocrinol 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
N/A: supplied as pre-filled solution or suspension, not lyophilized
After Reconstitution
Refrigerate at 2-8°C (36-46°F). Protect from light. Each ampule is single-use; discard any unused portion.
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Pasireotide (Signifor) is FDA-approved for Cushing's disease and acromegaly. Its 30-40 fold higher SSTR5 affinity compared to octreotide makes it particularly effective against corticotroph adenomas that express SSTR5 predominantly. The Phase 3 PASPORT trial showed normalized urinary free cortisol in 15-26% of Cushing's disease patients.

For Cushing's disease (SC): 600 mcg subcutaneous twice daily, titrated to 900 mcg twice daily based on response. For acromegaly (LAR): 40 mg intramuscular every 4 weeks, with titration to 60 mg monthly. The SC formulation requires refrigeration and twice-daily injection.

Hyperglycemia is the dominant safety concern: 73% of patients in the Cushing's trials developed glucose elevations, and roughly 30% required new diabetes medication. This exceeds other somatostatin analogs because SSTR5 agonism directly suppresses insulin secretion. Diarrhea (58%), nausea (52%), gallstones (30%), and headache (28%) are also common. Glucose monitoring is mandatory.

Pasireotide binds all five somatostatin receptor subtypes, with particularly high affinity for SSTR5 (30-40x more than octreotide) and SSTR1 (30x). Octreotide primarily targets SSTR2. This broader receptor profile makes pasireotide effective in Cushing's disease where octreotide typically fails, but the SSTR5 affinity also drives worse hyperglycemia.

The half-life of Pasireotide (Signifor) is ~12 hours (subcutaneous). This determines how frequently you need to dose for consistent blood levels.